Neurocess raises €18M Series B to scale Alzheimer's EEG screening across European primary care
Summary
Amsterdam-based Neurocess secured €18M Series B led by Forbion, with Sofinnova Partners and Inkef Capital, following successful 1,000-patient Dutch primary care pilot demonstrating 81% sensitivity for identifying MCI and early Alzheimer's from a 20-minute EEG. German and French market entries planned for 2025 with primary care and memory clinic channels.
Why it matters
Series B funding following a 1,000-patient primary care pilot with 81% sensitivity positions Neurocess as the most commercially validated EEG-based Alzheimer's screening company in Europe. Forbion and Sofinnova co-investing — both neuroscience-focused European VCs — signals strong specialist investor conviction in the technology and the market timing.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial